It depends on why they couldn't be patented. There's a nasty interaction between regulatory delay and patent terms starting at application which means that drugs that don't have huge markets don't get developed, but I'm pretty sure that you're not referring to those.
Let me guess - you think that there are substances which are unpatentable because they fail the novelty test but have great utility as drugs. If said utility is newly discovered, that satisfies the novelty test. If said utility is "folk medicine", then the only thing stopping anyone from selling them as drugs is the regulatory testing costs.... (Drugs don't have to be patented.)
The big scramble to re-purpose drugs is while they're still patented by one manufacturer. Once someone like Mylan is manufacturing it as a generic, doing research for "novel" forms is only helping your competition.
Umm, that's an argument against regulation. Regulation is imposing a cost that can't be recovered.
Note that the initial testing established "safe" (for some definition of "safe"), so any regulation-required testing is mostly for efficacy.
Combine that with the headstart of stem cell research the UK and Germany has, and we'll like see some cost-saving medical breakthroughs coming out of that part of the world in the next 3-5 years.
Oh, and a zero regulation environment? There's always going to be liability for "your drug killed people". In a zero regulation environment that cost is going to be incredibly high. Or your placebo drug is going to CAUSE economic damage by killing productive workers.
Your model of regulation/no-regulation is far too simple. As always, there is a sweet spot somewhere in the middle where both the public (consumer) and the corporation (producer) benefit.
And as always, if the cost of new drug (say an AIDS cure) is prohibitively high, a government may subsidize the process. Or even simply provide capital incentive (say a $2 billion winner take all prize, like an X-Prize for drugs).